EFFECTS OF EMPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE FROM JAPAN: EXPLORATORY ANALYSES FROM EMPA-KIDNEY
Journal article
HERRINGTON W., (2024), Clinical and Experimental Nephrology
Mechanisms of rosuvastatin-related acute kidney injury following cardiac surgery: the STICS trial.
Journal article
Wijesurendra RS. et al, (2024), Eur Heart J, 45, 629 - 631
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None. et al, (2024), Nat Commun, 15
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Journal article
Mayne K. et al, (2023), Journal of the American Society of Nephrology
Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial
Journal article
LANDRAY M. et al, (2023), Lancet Child and Adolescent Health
Delivering trials in the NHS: more than worth it.
Journal article
Haynes R. et al, (2023), Clin Med (Lond), 23, 525 - 526
Accelerating clinical trials: time to turn words into action.
Other
Landray MJ. et al, (2023), Lancet, 402, 165 - 168
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
Journal article
HERRINGTON W. et al, (2023), Kidney International Reports
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
Horby PW. et al, (2023)
Sacubitril/valsartan in Peritoneal Dialysis – Lessons from a Pharmacokinetic Study
Report
Judge P., (2023)
Randomised controlled trials for mpox in endemic countries.
Journal article
Rojek A. et al, (2023), Lancet Infect Dis
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study.
Journal article
Donovan K. et al, (2023), Clin J Am Soc Nephrol, 18, 17 - 27
Mechanisms and Predictors of Acute Kidney Injury with Perioperative Rosuvastatin in Patients Undergoing Cardiac Surgery
Preprint
Wijesurendra RS. et al, (2023)
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: the DECODE-CKD trial.
Journal article
Bartholdy KV. et al, (2022), Kidney360
Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.
Journal article
Staplin N. et al, (2022), Hypertension, 79, 2671 - 2681
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Journal article
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801
Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368